問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Bei-Hu Branch  (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

徐思淳
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐思淳

National Taiwan University Hospital

Division of Others

List

9Cases

2016-12-13 - 2022-05-05

Phase III

Completed
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)

  • Condition/Disease

    Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

  • Test Drug

    Venetoclax (ABT-199, GDC-0199)

Participate Sites
4Sites

Terminated3Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2024-12-01 - 2024-12-02

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-09-01 - 2026-10-02

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-05-01 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-04-01 - 2027-04-24

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-01 - 2021-09-10

Phase III

Completed
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

  • Condition/Disease

    Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

  • Test Drug

    CTL019

Participate Sites
1Sites

Recruiting1Sites

2023-06-01 - 2032-02-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-11-01 - 2035-05-31

Phase III

Active
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy

  • Condition/Disease

    B-cell Non-Hodgkin Lymphoma

  • Test Drug

    CTL019

Participate Sites
1Sites

Recruiting1Sites

2018-09-01 - 2026-10-02

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERY LOW, LOW OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES (MDS) IN ESA NAiVE SUBJECTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS

  • Condition/Disease

    Myelodysplastic Syndromes

  • Test Drug

    Luspatercept; Epoetin alfa

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB